2019, Communication and HIPAA - Pharmacist Digest

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

JULY 2, 2024

As noted in our previous communications, while the NHC would prefer a more traditional Notice and Comment rulemaking opportunity that would ensure the Agency directly responds to stakeholder feedback, we welcome this opportunity to express our reactions to CMS’ thinking on the negotiation program.

Drug Pricing

Drug Pricing Insurance Coverage and Processing Labelling HIPAA

Ep. 007 – Holly Henry and Kamran Shah Podcast Transcript

Pharma Marketing Network

JUNE 8, 2020

When you think of healthcare, from a HIPAA standpoint like tying everything back just like an individual does, you know start drawing some boundaries. Kamran (KH): I think one thing I always think of is the pharmaceutical industry is probably more privacy minded than most just because of HIPAA and other regulations we have to work under.

HIPAA

HIPAA Pharmaceutical Companies Pharmaceutical Companies Communication

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Ep. 007 – Holly Henry and Kamran Shah Podcast Transcript

Stay Connected